A Study of Cotadutide in Participants Who Have Chronic Kidney Disease with Type 2 Diabetes Mellitus

Study identifier:D5676C00001

ClinicalTrials.gov identifier:NCT04515849

EudraCT identifier:2020-000255-12

CTIS identifier:N/A

Study Complete

Official Title

A Phase 2b, Multicentre, Randomised, Double-blind, Placebo-controlled, and Open-label Comparator Study of Cotadutide in Participants Who Have Chronic Kidney Disease with Type 2 Diabetes Mellitus

Medical condition

Type 2 Diabetes Mellitus

Phase

Phase 2

Healthy volunteers

No

Study drug

Cotadutide 100 micrograms, Cotadutide 300 micrograms, Cotadutide 600 micrograms, Semaglutide, Placebo

Sex

All

Actual Enrollment

248

Study type

Interventional

Age

18 Years - 79 Years

Date

Study Start Date: 31 Aug 2020
Primary Completion Date: 08 Mar 2022
Study Completion Date: 08 Mar 2022

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria